Three GLP-1 RA RCTs found that people taking it versus those on second-line diabetes medications for five years a 53% decrease risk of developing dementia, and a reduced risk of cognitive impairment.33 Findings from our meta-analysis of case-control studies with 5–17 years of follow-up showed an associated reduced risk of 27%. The gene discussed is GLP1R; the disease is dementia.